Dosing voriconazole in an obese patient

Clinical Infectious Diseases

Volumn 53, Issue 7, 2011, Pages 745-

  Dickmeyer, Natalie J ^a   Kiel, Patrick J ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; MICAFUNGIN; VANCOMYCIN; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; CASE REPORT; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LETTER; LOADING DRUG DOSE; MALE; OBESITY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ADULT; ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; INFUSIONS, INTRAVENOUS; MALE; MYCOSES; OBESITY; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 80052475577     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir511     Document Type: Letter

References (2)

1. Bruggemann RJ, Blijlevens NM, Burger Dm, Franke B, Troke PF, Donnelly JP. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2010; 65:107-13.
2. Manjunath PP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011; 55:2601-5.